Epigenetic Regulation of HSD11B2 Gene by Promoter Methylation in Glucocorticoid-Treated Patients

Abstract
Background: A reduced activity of the 11 beta-hydroxysteroid dehydrogenase 2 (11 beta-HSD2) causes hypertension by conferring aldosterone selectivity to mineralocorticoid receptors and eventually impairing the tetrahydrocortisol-versus tetrahydrocortisone-metabolites (THFs/THE) shuttle. The 11 beta-HSD2 function is modulated by glucocorticoid treatment that may induce hypertension through a mechanism mostly unknown. Promoter methylation, one of the main epigenetic and potentially modifiable feature of DNA, regulates HSD11B2 gene expression and relates to the development of arterial hypertension.

Objective: To explore the mechanism by which steroid therapy influences blood pressure we investigated the effect of glucocorticoid-treatment on HSD11B2 promoter methylation and THFs/THE ratio, that reflects the 11 beta-HSD2 activity.

Method: We determined urinary THFs/THE ratio by gas chromatography/mass spectrometry and HSD11B2 methylation in promoter Region 1 and 2 using bisulfite-pyrosequencing in DNA from peripheral blood mononuclear cells (PBMCs) of six normotensive subjects affected by autoimmune diseases at three time points: T0) baseline, T1) following one-month prednisone therapy (0.5-1 mg/kg daily), and T2) at least one year after withdrawal.

Results: Glucocorticoid treatment was associated with the increase of HSD11B2 promoter methylation, that was significant for Region 1 (T0 2.4%, T1 2.8%, \( P=0.046 \)), and the concomitant raise of THFs/THE ratio (T0 1.29 ± 0.80, T1 4.10 ± 1.62, \( P=0.043 \)). After glucocorticoid-withdrawal (T2) both parameters decreased (methylation 1.9%; THFs/THE ratio 1.09), although not significantly. A significant positive correlation was observed between HSD11B2 promoter methylation and the THFs/THE ratio.


Keywords: HSD11B2; Hypertension; Cortisone; Epigenetics; DNA methylation

Abbreviations: 11 beta-HSD2: 11 Beta-Hydroxysteroid Dehydrogenase 2; THFs/THE: Tetrahydrocortisol/Tetrahydrocortisone; PBMCs: Peripheral Blood Mononuclear Cells; THF: Tetrahydrocortisol; αTHF: 5α-Tetrahydrocortisol; THE: Tetrahydrocortisone

Received: December 24, 2015; Accepted: January 22, 2016; Published: January 30, 2016

Corresponding author: Simonetta Friso

University of Verona, School of Medicine, Department of Medicine, Policlinico “G.B. Rossi”, P.le L.A. Scuro 10, 37134 Verona, Italy.

* These two authors equally contributed to this work

Tel: +39-045-8126369
Fax: +39-045-8027473

Introduction

The function of 11 beta-hydroxysteroid dehydrogenase type 2 (11 beta-HSD2) (EC 1.1.1.146) has a prominent role in essential hypertension [1-3] where a loss of its activity leads towards the activation of mineralocorticoid receptors by cortisol causing renal sodium retention [4] and high blood pressure [5, 6]. The HSD11B2 mRNA expression, furthermore, has been shown to be inversely related to urinary tetrahydrocortisol (THFs)/tetrahydrocortisone (THE) ratio [7], evidence that the THFs/THE ratio depends on the 11beta-HSD2 activity [8, 9] and may, therefore, represent a useful surrogate biomarker of the 11beta-HSD2 enzyme function [10]. Interestingly, promoter methylation at HSD11B2 site was demonstrated to be a functional mechanism for the transcriptional regulation of this gene and, thus, a reliable indicator of 11beta-HSD2 enzyme activity [11].

In a previous study [12] we observed that glucocorticoid-treated patients developing arterial hypertension showed a higher HSD11B2 promoter methylation concomitant with a higher urinary THFs/THE ratio. Furthermore, essential hypertensive patients with elevated urinary THFs/THE ratio showed higher HSD11B2 promoter methylation [12]. It is well-established that epigenetic mechanisms are potentially reversible, whereas the hypothesis that cortisol might transiently modulate HSD11B2 promoter methylation and eventually influence urinary THFs/THE ratio and the onset of hypertension needs to be confirmed. In fact this mechanism could be proven by assessing the gene promoter methylation and the urinary THFs/THE ratio before and during steroid therapy and after therapy withdrawal.

Precisely to address this hypothesis and with the aim of unraveling a possible role of epigenetic phenomena as the potential underlying mechanism in the pathogenesis of steroid-therapy-induced arterial hypertension, we designed the present study. Patients affected by rheumatologic diseases requiring the usage of prednisone for the acute phase of disease, were evaluated for the HSD11B2 promoter methylation status as well as for urinary THFs/THE ratio before, during and after withdrawal of prednisone therapy.

Materials and Method

Study design

The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Ethical Review Board of the University of Verona School of Medicine Hospital (Verona, Italy). Six subjects were enrolled among those referring to the Unit of Clinical Immunology of the Verona University Hospital (Verona, Italy) and written informed consent was obtained from each patient after a detailed explanation of the study. Patients were four males and two females (age range 34-60 years), prescribed to undergo prednisone therapy for autoimmune diseases in active phase (four sarcoidosis, one autoimmune eosinophilia and one autoimmune neurosensorial hypoacusia). All patients ingested 75 mg of prednisone daily (about 1 mg/kg per day), except the patient affected by autoimmune neurosensorial hypoacusia (37.5 mg per day, 0.5 mg/kg per day), for a period of time of one month. After the remission of the disease verified by clinical and biochemical analysis, patients started a prednisone slow décalage regimen up to the complete withdrawal of glucocorticoid therapy. The molecular and biochemical parameters were evaluated at enrolment (T0), at one month of therapy (T1) and at more than one year of complete withdrawal of steroid therapy (T2). No one of the patient was affected by hypertension nor was taking any other drug before and during therapy and after prednisone therapy suspension.

Biochemical analyses and urinary steroid metabolites

Venous blood samples were collected into EDTA-containing Vacutainer® tubes after overnight fasting for routine analysis including plasma creatinine and serum/urinary electrolytes. Cortisol was measured by a chemiluminescent enzyme immunoassay (Immulite® 2000 Cortisol, Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA).

Samples for aldosterone and renin assay were collected midmorning (09:00–10:00 h) and the patient was maintained at least 30 min in the upright posture and 10 min in the seated position. Renin was measured as direct active renin by the Liaison® Direct Renin assay and aldosterone by RIA (Radio Immuno Assay) (both by Sorin Biomedical Diagnostics, Vercelli, Italy) [13].

Urinary tetrahydrocortisol (THF), 5α-tetrahydrocortisol (αTHF) and tetrahydrocortisone (THE) were analyzed by gas chromatography/mass spectrometry [14, 15].

DNA methylation analysis by bisulfite pyrosequencing

DNA extraction from peripheral blood mononuclear cells (PBMCs): Blood samples were drawn in EDTA-containing BD Vacutainer® tubes, centrifuged at 2,500 g x g for 15 min at 4°C and the PBMCs collected. DNA was extracted from PBMCs samples with a standard phenol/chloroform procedure and DNA concentration and purity were assessed by NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE) and DNA was stored at -20°C.

HSD11B2 gene promoter bisulfite pyrosequencing: Pyrosequencing analysis was performed on two HSD11B2 promoter regions, namely Region 1 (bases -419 to -177, relative to the start of transcription) and Region 2 (bases -692 to -595, relative to the start of transcription). Genomic DNA (20 ng) was modified by sodium bisulfite using the EZ DNA Methylation kit (ZYMO Research, Orange, CA, USA) according to the manufacturer’s instructions.

The Region 1 was amplified using a couple of primers (Table 1) designed by PSQ Assay Design (Biotage AB, Uppsala, Sweden); to avoid the possible influence of methylation status on the amplification reaction, primers were designed in CpG-free regions. The Region 2 was amplified with previously reported primers [16] (Table 1).

The amplification reactions were performed in a 25 μL reaction volume with the primer sets and 5 Units of Taq polymerase.
Distribution of continuous variables is expressed as mean ± SD. The correlation between variables was evaluated using Pearson’s correlation coefficient. The analysis of differences between mean values at T0, T1, and T2 time points was undertaken by non-parametric Wilcoxon test for paired samples. Repeated measures were further investigated using linear quantile mixed-effect models [17]. The two approaches yielded comparable results. Statistical analysis was performed using the IBM SPSS 20 statistical software (IBM Inc, Amonk, NY, USA) and R 3.1.3 (R Foundation for Statistical Computing, Vienna) with the lqmm package [17].

Results

Table 2 shows the clinical and biochemical characteristics of the patients at the three time points: baseline (T0), following one-month prednisone therapy (T1), and at least one year after prednisone withdrawal (T2). As shown, systolic blood pressure slightly increased at T1 and decreased at T2 and diastolic blood pressure showed a mild increase at T1, but these differences did not reach the statistical significance. The THFs/THE ratio significantly increased after prednisone therapy (T0 vs. T1, P=0.043) and decreased after therapy withdrawal even if the difference did not reach the statistical significance (T1 vs. T2, P=0.068). The comparison was performed by non-parametric Wilcoxon test for paired samples. *P<0.05.

![Figure 1](image1.png)

Figure 1 Mean THFs/THE ratio values at baseline (T0), after-prednisone therapy (T1) and after-prednisone withdrawal (T2): The THFs/THE ratio significantly increased after prednisone therapy (T0 vs. T1, P=0.043) and decreased after therapy withdrawal even if the difference did not reach the statistical significance (T1 vs. T2, P=0.068). The comparison was performed by non-parametric Wilcoxon test for paired samples. *P<0.05.

A positive correlation was observed between HSD11B2 promoter methylation at Region 2 and the THFs/THE ratio (Pearson’s correlation coefficient=0.537, P=0.039).

Discussion

This study shows that HSD11B2 promoter methylation increased after glucocorticoid therapy and decreased after its withdrawal in PBMCs DNA of patients taking prednisone at high-dose for one month. These changes clearly paralleled the increase and decrease of THFs/THE ratio, a well-recognized surrogate biochemical marker of the 11beta-HSD2 enzyme function.
Compared to previous studies that used methyl-specific PCR, bisulfite pyrosequencing can more precisely measure the methylation status of each CpG site and therefore substantiate previous findings [12].

The higher methylation at HSD11B2 promoter following prednisone treatment and its trend to decrease after therapy interruption with a concomitant increase and subsequent decrease of THFs/THE ratio are consistent with the well-described functional role of promoter methylation [18] in the transcriptional repression of HSD11B2 [11, 12] and ultimately in the regulation of enzyme activity.

A trend towards the increase of blood pressure following prednisone therapy was also documented, although the difference did not reach the statistical significance. This result can be explained by the relatively short period of steroid treatment in patients that were normotensive at baseline. The THFs/THE ratio and HSD11B2 promoter methylation seems more sensitive to steroid therapy than the modification of blood pressure.

While these findings substantiate our previous study [12], they suggest some interesting considerations. They confirm the hypothesis that the altered function of 11beta-HSD2 may represent one of the possible mechanisms underlying the pathogenesis of hypertension during steroid therapy. Moreover, they highlight the involvement of an epigenetically-driven gene regulation mechanism by methylation at HSD11B2 promoter site. Although it is well-established that epigenetic phenomena are potentially reversible, the present observation of their modulation in patients undergoing steroid therapy, as it specifically refers to HSD11B2 promoter methylation is an interesting element of novelty. Moreover, the demonstration that HSD11B2 promoter methylation is modifiable and leads to enzyme activity modulation as proven by changes observed in the THFs/THE ratio, may explain the described reversibility of hypertension developing under steroid therapy regimen.

A key point for discussion relies on steroid therapy dosage, timing and period after withdrawal in modulating the HSD11B2 promoter methylation status. It cannot be excluded, in fact, that different dosage or timing of administration or a free-from-steroid-therapy period might influence methylation at HSD11B2 promoter site. Since the significantly higher methylation was

### Table 2 Clinical and biochemical features of glucocorticoid-treated patients.

<table>
<thead>
<tr>
<th></th>
<th>T0</th>
<th>T1</th>
<th>T2</th>
<th>P*</th>
<th>P†</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP (mm Hg)</td>
<td>127 ± 6.1</td>
<td>131 ± 5.8</td>
<td>123 ± 5.0</td>
<td>N.S</td>
<td>N.S</td>
</tr>
<tr>
<td>DBP (mm Hg)</td>
<td>79 ± 5.8</td>
<td>84 ± 3.8</td>
<td>76 ± 11.1</td>
<td>N.S</td>
<td>N.S</td>
</tr>
<tr>
<td>S-Na⁺ (mmol/L)</td>
<td>140 ± 5.3</td>
<td>141 ± 3.0</td>
<td>141 ± 2.2</td>
<td>N.S</td>
<td>N.S</td>
</tr>
<tr>
<td>S-K⁺ (mmol/L)</td>
<td>3.85 ± 0.39</td>
<td>3.88 ± 0.41</td>
<td>3.73 ± 0.44</td>
<td>N.S</td>
<td>N.S</td>
</tr>
<tr>
<td>S-CI (mmol/L)</td>
<td>104 ± 2.3</td>
<td>104 ± 3.1</td>
<td>104 ± 1.3</td>
<td>N.S</td>
<td>N.S</td>
</tr>
<tr>
<td>U-Na⁺ (mmol/24 h)</td>
<td>77.3 ± 20.1</td>
<td>97.2 ± 54.2</td>
<td>70.0 ± 20.6</td>
<td>N.S</td>
<td>N.S</td>
</tr>
<tr>
<td>U-K⁺ (mmol/24 h)</td>
<td>59.0 ± 16.4</td>
<td>46.0 ± 10.7</td>
<td>40.7 ± 14.6</td>
<td>N.S</td>
<td>N.S</td>
</tr>
<tr>
<td>U-Cl⁻ (mmol/24 h)</td>
<td>98.7 ± 54.5</td>
<td>104.3 ± 65.7</td>
<td>78.5 ± 28.1</td>
<td>N.S</td>
<td>N.S</td>
</tr>
<tr>
<td>Renin (pg/mL)</td>
<td>11.5 ± 15.4</td>
<td>21.8 ± 14.2</td>
<td>8.21 ± 4.47</td>
<td>N.S</td>
<td>N.S</td>
</tr>
<tr>
<td>Aldosterone (pg/mL)</td>
<td>165 ± 29.2</td>
<td>232 ± 65.4</td>
<td>227 ± 81.4</td>
<td>0.028 N.S</td>
<td></td>
</tr>
<tr>
<td>ARR</td>
<td>36.1 ± 28.2</td>
<td>20.7 ± 21.5</td>
<td>36.8 ± 27.3</td>
<td>N.S</td>
<td>N.S</td>
</tr>
<tr>
<td>THF (mg/24 h)</td>
<td>2.43 ± 1.28</td>
<td>0.43 ± 0.19</td>
<td>5.52 ± 8.14</td>
<td>0.028 N.S</td>
<td></td>
</tr>
<tr>
<td>α-THF (mg/24 h)</td>
<td>2.33 ± 2.15</td>
<td>0.26 ± 0.27</td>
<td>2.05 ± 2.46</td>
<td>0.028 N.S</td>
<td></td>
</tr>
<tr>
<td>THE (mg/24 h)</td>
<td>3.09 ± 2.37</td>
<td>0.18 ± 0.09</td>
<td>6.46 ± 8.73</td>
<td>0.028 N.S</td>
<td></td>
</tr>
<tr>
<td>THFs/THE ratio</td>
<td>1.29 ± 0.80</td>
<td>4.10 ± 1.62</td>
<td>1.09 ± 0.36</td>
<td>0.043 N.S</td>
<td></td>
</tr>
</tbody>
</table>

Data are means ± SD. P-values refer to paired samples non-parametric Wilcoxon test for the comparison between T0 and T1 (*) or for the comparison between T1 and T2 (†).

T0, baseline; T1, after-prednisone therapy; T2, after-prednisone withdrawal; SBP, systolic blood pressure; DBP, diastolic blood pressure; ARR, aldosterone to renin ratio; THF, urinary tetrahydrocortisol; α-THF, 5α-tetrahydrocortisol; THE, tetrahydrocortisone; THFs/THE ratio, tetrahydrocortisol-versus tetrahydrocortisone-metabolites ratio.

Figure 2 DNA methylation levels at HSD11B2 promoter Region 1 and Region 2 sites: Region 1 showed a statistically significant increase in DNA methylation levels after prednisone therapy (T0 vs. T1, P=0.046). After prednisone withdrawal, DNA methylation values dropped from 2.8% to 1.9%, although this decrease did not reach statistical significance. DNA methylation levels of Region 2 showed an increase after prednisone therapy (T0=6.2%, T1=6.9%) and a decrease after prednisone withdrawal (T1=6.9%, T2=6.3%). However, these differences were not statistically significant. *P<0.05.
observed after one month of therapy, one could speculate that its drop after suspension may possibly occur even in a time shorter than one year.

The lack of statistical significance in the decrease of methylation values after prednisone withdrawal may also be related to the inherent stochastic nature of epigenetic processes [19] and, in the present study, to the relatively small number of participating subjects. Although the rather small number of patients studied is one of the limitations of this study, their homogeneity in terms of clinical characteristics, dosage and timing of prednisone utilized and time of analysis after withdrawal may give reason, at least partially, of our results in terms of functional epigenetic modulation. Indeed, a larger study is needed to confirm the present findings. Moreover, further ad hoc studies are certainly warranted to define the minimal dosage needed to modify the enzyme function by modulating HSD11B2 gene promoter methylation, and the required timing to reverse the phenomenon.

The methylation status observed at Region 1 of the HSD11B2 promoter confirms our previous results on the functional effect of methylation at this promoter region, results obtained with a different methodological approach [12].

As previously reported by others [16] we confirm the higher mean levels of methylation at HSD11B2 Region 2 as compared with Region 1 (Figure 2). The variations associated to prednisone therapy in Region 2 were similar, although not significant, to those observed in Region 1.

It could be speculated that the differential effect on methylation may be linked to other transcriptional regulatory factors at specific sites [20]. This hypothesis, however, needs further ad hoc studies.

Epigenetic mechanisms, including DNA methylation, are considered tissue-specific, however, several studies already showed that methylation status, either genomic or gene-specific, in PBMCs DNA may reflect a systemic epigenetic fingerprint [21]. These results are, therefore, of interest in the perspective of a potential use of PBMCs DNA methylation as a molecular biomarker for clinical purposes.

The mechanisms responsible of the higher HSD11B2 promoter methylation observed in prednisone-treated patients are yet matter of speculation. It is well known the link between DNA methylation and one-carbon metabolism for the provision of methyl groups by S-adenosylmethionine for the methylation reaction catalyzed by methyltransferases [22]. On another hand, glucocorticoids are able to up-regulate S-adenosylmethionine synthase activity [20, 23, 24]. In a rodent experimental model, a role for glucocorticoids in affecting one-carbon metabolism has been suggested [25-27] to modulate DNA methylation [28, 29]. A number of mechanisms have been certainly claimed for being involved in the pathogenesis of glucocorticoid-induced hypertension [30] where a role for epigenetics can be also considered.

Epigenetic phenomena, among which DNA methylation, are lately emerging as potential important mechanisms for regulation of transcriptional expression of genes implied in complex, multifactorial diseases such as the case of arterial hypertension [3]. The observation of the functional role of methylation at HSD11B2 gene promoter and, furthermore, the induction and reversibility of this phenomenon in association with high-dose glucocorticoid therapy is a novel finding of potential high interest.

In conclusion, this study shows that 11beta-HSD2 is dynamically regulated during glucocorticoid therapy by methylation at HSD11B2 gene promoter site. The enzyme activity is functionally influenced as shown by the altered THFs/THE ratio, a surrogate biochemical marker of 11beta-HSD2 enzyme function. Remarkably, the epigenetic regulation of HSD11B2 is induced during prednisone therapy and reverses after prednisone withdrawal. The methylation status of HSD11B2 observed in PBMCs DNA may be considered as a useful epigenetic molecular marker of steroid-induced hypertension.

Conflict of Interest

The authors declare that they have no conflict of interest.

Acknowledgement

The work was performed in part in the LURM (Laboratorio Universitario di Ricerca Medica) Research Center, University of Verona.
References


